| 1 |
Olanlokun JO, Oyebode OT, Popoola D, Bodede O, Idowu TO, Moodley R, Olorunsogo OO. In vitro effects of 2-methyl-3-propylbutane-1,4-diol purified from Alstonia boonei on erythrocyte membrane stabilization and mitochondrial membrane permeabilization. Chem Biol Drug Des 2023;101:678-89. [PMID: 36323654 DOI: 10.1111/cbdd.14168] [Reference Citation Analysis]
|
| 2 |
Parrasia S, Szabò I, Zoratti M, Biasutto L. Peptides as Pharmacological Carriers to the Brain: Promises, Shortcomings and Challenges. Mol Pharm 2022. [PMID: 36174227 DOI: 10.1021/acs.molpharmaceut.2c00523] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 3 |
Li Y, Ruan S, Guo J, He Z, Xia Q, Wu T, Wang Z, Li Z, Hu H, Jing Q, Hou X, He Y, Zhang B, Feng N, Zhang Y. B16F10 Cell Membrane-Based Nanovesicles for Melanoma Therapy Are Superior to Hyaluronic Acid-Modified Nanocarriers. Mol Pharm 2022. [PMID: 35850109 DOI: 10.1021/acs.molpharmaceut.2c00212] [Reference Citation Analysis]
|
| 4 |
Kravenska Y, Checchetto V, Szabo I. Routes for Potassium Ions across Mitochondrial Membranes: A Biophysical Point of View with Special Focus on the ATP-Sensitive K+ Channel. Biomolecules 2021;11:1172. [PMID: 34439838 DOI: 10.3390/biom11081172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 5 |
Biasutto L, Mattarei A, Paradisi C. Synthesis and Testing of Novel Isomeric Mitochondriotropic Derivatives of Resveratrol and Quercetin. Methods Mol Biol 2021;2275:141-60. [PMID: 34118036 DOI: 10.1007/978-1-0716-1262-0_9] [Reference Citation Analysis]
|
| 6 |
Checchetto V, Leanza L, De Stefani D, Rizzuto R, Gulbins E, Szabo I. Mitochondrial K+ channels and their implications for disease mechanisms. Pharmacol Ther 2021;227:107874. [PMID: 33930454 DOI: 10.1016/j.pharmthera.2021.107874] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 7 |
Menezes JCJMDS, Diederich MF. Bioactivity of natural biflavonoids in metabolism-related disease and cancer therapies. Pharmacol Res 2021;167:105525. [PMID: 33667686 DOI: 10.1016/j.phrs.2021.105525] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 8 |
Aburel OM, Pavel IZ, Dănilă MD, Lelcu T, Roi A, Lighezan R, Muntean DM, Rusu LC. Pleiotropic Effects of Eugenol: The Good, the Bad, and the Unknown. Oxid Med Cell Longev 2021;2021:3165159. [PMID: 33747344 DOI: 10.1155/2021/3165159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 9 |
Chavarria D, Da Silva O, Benfeito S, Barreiro S, Garrido J, Cagide F, Soares P, Remião F, Brazzolotto X, Nachon F, Oliveira PJ, Dias J, Borges F. Fine-Tuning the Biological Profile of Multitarget Mitochondriotropic Antioxidants for Neurodegenerative Diseases. Antioxidants (Basel) 2021;10:329. [PMID: 33672269 DOI: 10.3390/antiox10020329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Shi Y, Wang S, Wu J, Jin X, You J. Pharmaceutical strategies for endoplasmic reticulum-targeting and their prospects of application. Journal of Controlled Release 2021;329:337-52. [DOI: 10.1016/j.jconrel.2020.11.054] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
|
| 11 |
Szabo I, Zoratti M, Biasutto L. Targeting mitochondrial ion channels for cancer therapy. Redox Biol 2021;42:101846. [PMID: 33419703 DOI: 10.1016/j.redox.2020.101846] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 12 |
Lin SR, Chen YH, Tseng FJ, Weng CF. The production and bioactivity of prodigiosin: quo vadis? Drug Discov Today 2020;25:828-36. [PMID: 32251776 DOI: 10.1016/j.drudis.2020.03.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
